Interferon alfa-2a (Roferon-A)

General information

Class/mechanism: Immune system activator; binds to human type 1 interferon, activating downstream intracellular signal transduction pathways initially mediated by the JAK/STAT pathway. Interferon α-2a activates multiple biologic effects which are not fully understood.^[1]^[2]
Route: SC
Extravasation: n/a

For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.^[1]

Diseases for which it is established (work in progress)

Diseases for which it is used

Diseases for which it was used

Patient drug information

History of changes in FDA indication

1986-06-04: Initial FDA approval for treatment of patients 18 years of age or older with hairy cell leukemia (Based on N2752)
Uncertain date: In addition, it is indicated for chronic phase, Philadelphia chromosome (Ph) positive chronic myelogenous leukemia (CML) patients who are minimally pretreated (within 1 year of diagnosis). (Based on DM 84-38 & MI400)

Also known as

Brand name: Laroferon, Roferon-A

References

[insert-1] 1.0 ^1.1 ^1.2 Interferon alfa-2a (Roferon-A) package insert

[2] Interferon alfa-2a (Roferon-A) package insert (locally hosted backup)

[3] Interferon alfa-2a (Roferon-A) patient drug information (Chemocare)

[1]

[2]

[3]